FDA Drug recall D-1612-2020
WP Thyroid, Westhroid Pure, 1.75 Grain (113.75 mg) Thyroid USP, packaged in a) 1,000 Tablets, NDC 64727-6150-2
- FDA Drug
- Class II
- terminated
- Published 2020-09-23
On 2020-09-23 the FDA classified a Class II recall of WP Thyroid, Westhroid Pure, 1.75 Grain (113.75 mg) Thyroid USP, packaged in a) 1,000 Tablets, NDC 64727-6150-2 by Rlc Labs, citing CGMP Deviations: manufactured under the same conditions as those found to be subpotent.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-1612-2020 |
| Classification | Class II |
| Status | terminated |
| Initiated | 2020-08-25 |
| Published | 2020-09-23 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Rlc Labs |
| Distribution | US |
Product
WP Thyroid, Westhroid Pure, 1.75 Grain (113.75 mg) Thyroid USP, packaged in a) 1,000 Tablets, NDC 64727-6150-2 ; b) 30 Tablets, NDC 64727-6150-4; c) 60 Tablets, NDC 64727-6150-5; d) 90 Tablets, NDC 64727-6150-6; e) 100 Tablets, NDC 64727-6150-1; Rx only, Manufactured by: RLC Labs Phoenix, AZ 85034
Reason
CGMP Deviations: manufactured under the same conditions as those found to be subpotent.
Identifiers
| code_info | All lots with expiry between 10/2020-07/2023 |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1612-2020%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.